Molecular imaging with VEGFR2 targeted MBs has been used for monitoring therapy effects in an experimental CRC model 36 and clinically for breast, ovarian, prostate 37, 38 and renal cell cancer imaging 39 demonstrating widespread potential for VEGFR2 in cancer imaging and targeting. The gene discussed is KDR; the disease is renal cell adenocarcinoma.